Upload
pubricahealthcare
View
0
Download
0
Tags:
Embed Size (px)
DESCRIPTION
• Over the past few years, the magnitude of machine learning in the field of healthcare delivery setting becomes plentiful and captivating. • FDA is giving suggestions to provide well equipped regulated products. Pubrica is here to help you with the regulated for Bio-statistical consulting services. Full Information: https://bit.ly/37iY7ss Reference: https://pubrica.com/services/research-services/biostatistics-and-statistical-programming-services/ Why Pubrica? When you order our services, we promise you the following – Plagiarism free, always on Time, outstanding customer support, written to Standard, Unlimited Revisions support and High-quality Subject Matter Experts. Contact us : Web: https://pubrica.com/ Blog: https://pubrica.com/academy/ Email: [email protected] WhatsApp : +91 9884350006 United Kingdom: +44- 74248 10299
Citation preview
Copyright © 2020 pubrica. All rights reserved 1
An Overview of Regulatory Affairs, Causal Inference, Safe and Effective
Health Care in Machine Learning for Bio-Statistical Services
Dr. Nancy Agens, Head,
Technical Operations, Pubrica
In Brief
Over the past few years, the magnitude of
machine learning in the field of healthcare
delivery setting becomes plentiful and
captivating. Many regulatory sectors
noticing these developments and the FDA
has been appealing to provide bet machine
learning services with safe and productive
use. Despite having the limitations in
software-driven products, FDA leads to
giving a significant benefit of causal
inference for the development of machine
learning. FDA is giving suggestions to
provide well equipped regulated products.
Pubrica is here to help you with the
regulated for Bio-statistical consulting
services.
Keywords: Clinical biostatistics services,
biostatistics consulting services,
biostatistics CRO, Statistical
Programming Services, Bio-statistical
Services, biostatistics consulting firms,
Biostatistics for clinical research, statistics
in clinical trials, biostatistics in clinical
trials, biomedical studies, Biostatistics
Support Service, machine learning
services, healthcare services, machine
learning analysis.
I. INTRODUCTION
The significance of machine learning has
evolved globally, especially in th field of
medical and healthcare sectors. Many tools
are significant for various purposes likes
diagnosis, software tools for many clinical
findings in multiple areas. The machine
learning paves an easier way to clinical Bio-
statistical services using many software
tools. It creates an excellent standard on
radiology and cardiology and improves the
patient’s medical issues rapidly, more
comfortable decision making in clinical
trials. All these maintained by drafting a set
of regulations by various government
sectors around the world.
II. REGULATIONS FOR SAFE AND
EFFECTIVE HEALTH CARE MACHINE
LEARNING
FDA (food and Drug Administration)
FDA is a regulatory organization there to
perform the quality of any medical or
clinical testing equipment, medicines, or any
food-related products. FDA is looking to
provide the best facilities in health care
sectors through machine-learning artificial
intelligence services for the statistical
programming services. Though it is not an
urgent need for ML-driven tools, there are
few benefits of using ML-driven tools in
medical fields, says FDA
Applications
Instrumental usage
Machine implementation
Invitro reagents implantation
technology
Diagnostic kit
Copyright © 2020 pubrica. All rights reserved 2
Treatment for humans and animals.
FDA definition
The usage of ML can provide both physical
equipment and software tools. This software
device is known as SiMD (software in a
medical device). International medical
device regulators verify these software-
driven tools.
Challenges in SiMD
Cybersecurity
Management of data
Collection of data
Protecting information
To create opportunities in patient’s care
Limitations:
For some reasons, the FDA does not
regulate two applications of ML systems.
They are
Clinical design support software(CDS)
Laboratory developed tests.
The actual reason for exempting these uses
are CDS provide instance decision making,
which may affect in the future. On the other
side Laboratory, developed tests can access
only one available health care. FDA cannot
regulate these type of software.
Last year FDA released a paper after
conducting a serious discussion with the
regulatory members and proposed
“Regulatory Framework for Modifications
to Artificial Intelligence/Machine Learning
(AI/ML)-based Software as a Medical
Device.” for statistics in clinical research. It
includes some premarket research products
approval procedures that would delay the
ML process. Many Bio-statistical firms
raised few critics against it.
The objective of the proposal is to give
access to real-world data using ML
products more efficiently with some
regulatory barriers. It also includes some
real-world affirmations. Many people could
not be able to recognize this proposal. To
overcome this, the FDA officials spoke to
the public to create awareness about the
“approach of regulating algorithms”.
Regardless of all benefits and limitations,
ML is facing challenges in the development
of the safe and efficient product. Some of
the challenges are
ML identifications
ML predictions
ML recommendations
ML algorithms for diagnostic tools
To overcome this, Subbaswamy and Saria
provide some potential remedies by
discussing the statistical foundations in the
Bio-statistical analysis. Data curation of
individual patient’s health raises questions
for request algorithms to give a more
specific context.
Transfer learning
The process of learning a task from the
already-completed job through knowledge
transfer is called transfer learning.
However, this process is complicated. The
datasets can affect the algorithms, resulting
in the false provisional services in health
care analysis. This process is not allowed in
the medical sectors.
Biomarkers in FDA
In the process of validation of a biomedical
tool, biomarker validation is mandatory in
the clinical research services. There are so
many parameters for qualifying a
biomarker. The casual inference is a novel
digital biomarker validation.
An ML algorithm that detects the patient’s
therapy benefits may not be relevant unless
a casual inference tool access in that
biomarker. Some make a precise diagnosis
and treatment recommendations to
understand the factors in ML algorithms.
The production of digital biomarkers facing
more challenges to incentivizing parties in
health care sectors. R&D validated provide
significance in delivery of healthcare
services. Studies say that statistician’s tool
kit has grown fast, and various technical
tools have a development for causal
inference of machine learning in biomedical
investigations and reviews.
Copyright © 2020 pubrica. All rights reserved 2
III. CONCLUSION
Wrapping up, in a complex environment,
the role of regulatory affairs in biomedical
studies for machine learning is essential.
One of the easiest ways to support the
regulators is the usage of biomarkers in
healthcare tools. These regulations help to
provide better healthcare services under the
guidance of pubrica.
REFERENCES
1. Stern, A. D., & Price, W. N. (2020). Regulatory
oversight, causal inference, and safe and effective
health care machine learning. Biostatistics, 21(2),
363-367.
2. Cleland-Huang, J., Czauderna, A., Gibiec, M.,
&Emenecker, J. (2010, May). A machine learning
approach for tracing regulatory codes to product-
specific requirements. In Proceedings of the 32nd
ACM/IEEE International Conference on Software
Engineering-Volume 1 (pp. 155-164).
3. Hwang, T. J., Kesselheim, A. S., &Vokinger, K. N.
(2019). Lifecycle Regulation of Artificial
Intelligence–and Machine Learning-Based Software
Devices in Medicine. Jama, 322(23), 2285-2286.
4. Wiens, J., Saria, S., Sendak, M., Ghassemi, M., Liu,
V. X., Doshi-Velez, F., ...&Ossorio, P. N. (2019).
Not harm: a roadmap for responsible machine
learning for health care. Nature medicine, 25(9),
1337-1340.